Guan Hao Biotech acquires Hangzhou Huidisen Group

With the 1,8 billion RMB acquisition, Guan Hao Biotech will become China’s second largest pharmaceutical enterprise and extend ist business into regenerative medicine, cell therapy and other drugs. Huidisen is a leader in cephalosporin production. China Bio news...

Jinan City, Shandong, starts National R&D platform for new drugs

The Jinan Yao Valley biomedical industry base will focus on biological medicine, equipment, stem cell technology and precision medicine. At present, over 700 biomedical enterprises have settled in this park. China Bio news release, October 24, 2016